Increasing number of cancer cases, rising government initiatives and projects, new drug developments, and increasing demand for cancer-specific diagnostics are factors driving global tumor genomic market growth.

Vancouver, BC -- (SBWire) -- 04/15/2021 --The global tumor genomics market is expected to reach a market size of 56.54 Billion by 2028 and register a double-digit CAGR over the forecast period, according to latest analysis by Emergen Research. The steady projected growth can be attributed to technological innovations in the field of genomics. Mergers and acquisitions between key players in the field is another key factor driving market growth.

Increasing research on cancer, usage of genomic systems among academics and government institutions, and decreasing cost of sequencing is contributing significantly to growth in cancer diagnostics. 

To get a sample copy of the Global Tumor Genomic Market report, visit @ https://www.emergenresearch.com/request-sample/531   

Key Highlights of Report

In September 2018, Cancer Genetics Inc. and NovellusDx Ltd. signed a merger agreement in order to combine their data associated to tumor anatomy. The aim behind the merger is to enhance and accelerate the therapeutic development to improve treatment success rates for companies. With the proprietary technology and machine learning technology of NovellusDX Ltd., Cancer Genetics aims to form a leading oncology-focused precision medicine company.
Biomarkers play an important role in the detection of cancer and it may be used to detect early cancer symptoms or to perform differential diagnosis of cancerous tumors.
Revenue from the tumor genomic market in Asia Pacific is expected to expand at a rapid CAGR during the forecast period. This can be attributed to rising government funding for cancer detection and awareness, and introduction of state-of-the-art research institutions.
Key players in genomic biomarkers are Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Pacific Biosciences of California, Inc., NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., and PerkinElmer.

Tumor Genomic Market Segmentation:

Emergen Research has segmented the global tumor genomic market on the basis of technique, application, end-use, and region:

Technique Outlook (Revenue, USD Billion; 2021–2028)
Next Generation Sequencing Technique (NGS)
Polymerase Chain Reaction (PCR)
Microarray
In-Situ Hybridization (ISH)
Immunohistochemistry (ICH)
Others (Mass Spectrometry and Flow Cytometry)

Application Outlook (Revenue, USD Billion; 2021–2028)
Diagnostics and Monitoring
Drug Discovery and Development
Biomarker Discovery

End-use Outlook (Revenue, USD Billion; 2021–2028)
Academics and Research Organizations
Hospitals and Ambulatory Clinics
Clinical and Diagnostic Laboratories
Biotechnology and Pharmaceutical Company

Key Regions analyzed in the report include:

North America (U.S., Canada)
Europe (U.K., Italy, Germany, France, Rest of EU)
AsiaPacific (India, Japan, China, South Korea, Australia, Rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Request customization of the report @ https://www.emergenresearch.com/request-for-customization/531

Elucidating the competitive scenario of the Global Tumor Genomic Market:

The comprehensive global Tumor Genomic market analysis includes meaningful insights into the competitive spectrum of this business sphere. It goes on to enlist the detailed profiles of each market competitor.
The latest report includes the industry share, production facilities, development prospects,and geographies served by each market player.
The study also showcases the extensive product portfolios of the prominent market contenders and offers critical data and information about the application scope, as well as specifications of these products.
In addition, the study presents the fundamental market insights, pricing range of products offered by these companies, and the gross profits and losses experienced by these players throughout their market tenures.

Table of Content

Chapter 1. Methodology & Sources
    1.1. Market Definition
    1.2. Research Scope  
    1.3. Methodology
    1.4. Research Sources
          1.4.1. Primary
          1.4.2. Secondary
          1.4.3. Paid Sources
    1.5. Market Estimation Technique
Chapter 2. Executive Summary
    2.1. Summary Snapshot, 2020-2028
Chapter 3. Key Insights
Chapter 4. Tumor Genomics Market Segmentation & Impact Analysis
    4.1. Tumor Genomics Market Material Segmentation Analysis
    4.2. Industrial Outlook
          4.2.1. Market drivers analysis
                    4.2.1.1. Increasing number of cancer cases
                    4.2.1.2. Rising government initiatives and projects
                    4.2.1.3. Increasing demand for cancer specific diagnostics
                    4.2.1.4. Increasing use of biomarkers in cancer profiling
                    4.2.1.5. Introduction of cost-effective kits
                    4.2.1.6. Mergers and acquisitions between key players
          4.2.2. Market restraints analysis
                    4.2.2.1. High equipment cost
    4.3. Technological Insights 
    4.4. Regulatory Framework
    4.5. Porter's Five Forces Analysis
    4.6. Competitive Metric Space Analysis
    4.7. Price trend Analysis
    4.8. Covid-19 Impact Analysis

Chapter 5. Tumor Genomics Market By Technique Insights & Trends, Revenue (USD Billion)
    5.1. Technique and services Dynamics & Market Share, 2020 & 2028
          5.1.1. Next Generation Sequencing Technique (NGS)
          5.1.2. Polymerase Chain Reaction (PCR)
          5.1.3. Microarray
          5.1.4. In-Situ Hybridization (ISH)
          5.1.5. Immunohistochemistry (ICH)
          5.1.6. Others (Mass Spectrometry and Flow Cytometry) 

Chapter 6. Tumor Genomics Market By Application Insights & Trends Revenue (USD Billion)
    6.1. Application Dynamics & Market Share, 2020 & 2028
          6.1.1. Diagnostics and Monitoring
          6.1.2. Drug Discovery and Development
          6.1.3. Biomarker Discovery

CONTINUED..!!

For more details on the Global Tumor Genomic Market report, visit @ https://www.emergenresearch.com/industry-report/tumor-genomics-market

Thank you for reading our report. Please connect with us to know more about the report and its customization feature. Our team will ensure your queries are solved, and the report is customized to meet your requirements.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkdIn | Twitter | Blogs

Read Full Press Release: https://www.emergenresearch.com/press-release/global-tumor-genomic-market